Growth and continued competition in the contract clinical testing market
First written in FY2020-Q1. 11 of 22 entries say "Restated". Latest entry: 2026-11-11.
Bml moved to the "Worse" side of this theme in 2026.
2 other companies' latest entry also says "Restated".
- FY2026WorsenedAnnual report
「Against this economic backdrop, the contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in medical reimbursement rates for specimen testing, the business environment remains challenging because, in addition to rising costs, the burden of securing personnel has increased against a backdrop of labor shortages.」
Although medical fees have not been reduced in the contract clinical testing market, the challenging environment has become more severe as rising costs and the burden of securing personnel due to labor shortages have been added. - 2026-05-13WorsenedResults
「しかしながら、中東情勢の影響を注視する必要があり、金融資本市場の変動の影響やアメリカの通商政策をめぐる動向などにも引き続き注意する必要があります。」
中東情勢、金融資本市場の変動、アメリカの通商政策を引き続き外部環境として挙げている。 - FY2026-H1RestatedAnnual report
「Against this economic backdrop, the contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in medical reimbursement rates for specimen testing, the business environment remains challenging because various costs, including labor costs, are rising and competition among providers continues.」
Although medical fees have not been reduced, the company reconfirmed the challenging environment in the contract clinical testing market, where personnel and other costs are rising and competition among providers continues. - FY2025RestatedAnnual report
「Against this economic backdrop, the contract clinical testing industry is in a fiscal year in which medical reimbursement rates are revised every 2 years. In addition to lower medical reimbursement rates for specimen testing, the business environment remains challenging because labor and other costs are rising and competition among providers continues.」
The company reconfirmed the challenging environment in the contract clinical testing market, where medical fee reductions, rising costs and competition among providers continue. - FY2025-H1Continued reductions in medical fees and increases in personnel costsAnnual report
「Against this economic backdrop, 2024 is a fiscal year in which medical reimbursement rates are revised every 2 years. In addition to lower medical reimbursement rates for specimen testing, the business environment remains challenging because labor and other costs are rising and competition among providers continues.」
In addition to lower demand related to COVID-19 and higher costs, the market environment was described as being affected by reductions in medical fees for specimen testing and increases in personnel and other costs. - FY2024Declining COVID-19 demand and rising costs coexistAnnual report
「Against this economic backdrop, demand for COVID-19-related testing declined in the contract clinical testing industry as a result of COVID-19 being reclassified as a Category V infectious disease in May 2023. In addition, the business environment remains challenging because raw material and energy costs have risen and competition among providers continues.」
The decline in demand for COVID-19-related testing was attributed specifically to the reclassification as a Category V infectious disease, creating a market environment in which higher raw material and energy costs coexist with continued competition. - FY2024-Q3RestatedAnnual report
「Against this economic backdrop, the contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in the reimbursement points for specimen testing (official prices), the business environment remains challenging because the number of COVID-19-related tests (hereinafter, “COVID tests”) has declined and competition among providers continues.」
Although medical fee points were not reduced, the company reconfirmed the challenging market environment, with the decline in COVID-19 testing volumes and competition among providers continuing. - FY2024-Q2Continued decline in the number of COVID-19-related testsAnnual report
「Against this economic backdrop, the contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in the reimbursement points for specimen testing (official prices), the business environment remains challenging because the number of COVID-19-related tests has declined and competition among providers continues.」
Although medical fee points were not reduced following the medical fee revision, the decline in COVID-19-related testing volumes and continued competition were identified as factors contributing to the challenging environment in the contract clinical testing market. - FY2024-Q1Decline in the number of COVID-19-related testsAnnual report
「Although the number of existing tests contracted and revenue increased, both revenue and profit declined due to a decrease in the number of COVID-19-related tests.」
Although the number of existing tests contracted and revenue increased, the decline in COVID-19-related testing volumes was a factor behind the overall declines in revenue and profit. - FY2023-Q3RestatedAnnual report
「Against this economic backdrop, the number of patients visiting medical institutions has remained weak in the contract clinical testing industry due to the impact of medical reimbursement rate revisions and the spread of COVID-19. Competition with other companies in the industry also continues, and the business environment remains challenging.」
The company reconfirmed the challenging environment in the contract clinical testing market, where medical fee revisions, weak patient numbers and competition with other companies in the industry continue. - FY2023-Q2RestatedAnnual report
「Against this economic backdrop, the number of patients visiting medical institutions has remained weak in the contract clinical testing industry due to the impact of medical reimbursement rate revisions and the spread of COVID-19. Competition with other companies in the industry also continues, and the business environment remains challenging.」
The company reconfirmed the environment in the contract clinical testing market in which the impact of medical fee revisions, weak patient numbers and continued competition coexist. - FY2023-Q1Impact of medical fee revisions and weak patient numbersAnnual report
「Against this backdrop, the business environment in the contract clinical testing industry remains challenging due to the impact of medical reimbursement rate revisions, patient numbers remaining weak, and continued competition with other companies in the industry.」
The challenging environment resulting from medical fee revisions, weak patient numbers and continued competition has come to the fore, replacing the previously stated market expansion driven by COVID-19-related testing. - FY2022-Q3RestatedAnnual report
「Against this backdrop, although patient numbers in the contract clinical testing industry have remained weak due to the impact of COVID-19, the market has expanded as demand for COVID-19-related testing has grown. However, competition with other companies in the industry continues, and the business environment remains challenging.」
The company reconfirmed the challenging business environment in which weak patient numbers and market expansion driven by demand for COVID-19-related testing coexist, while competition with other companies in the industry continues. - FY2022-Q2RestatedAnnual report
「Against this backdrop, although patient numbers in the contract clinical testing industry have remained weak due to the impact of COVID-19, the market has expanded as demand for COVID-19-related testing has grown. However, competition with other companies in the industry continues, and the business environment remains challenging.」
The company reconfirmed the challenging business environment in which weak patient numbers and market expansion driven by demand for COVID-19-related testing coexist, while competition with other companies in the industry continues. - FY2022-Q1Market expansion driven by COVID-19-related testingAnnual report
「Against this backdrop, in the contract clinical testing industry, patient numbers remained weak due to the impact of COVID-19, but the market expanded as demand for COVID-19-related testing grew. However, restrictions on sales activities and competition with other companies in the industry continue, leaving the business environment challenging.」
The company stated that the market expanded as demand for COVID-19-related testing grew despite weak patient numbers, specifying the factor driving market growth. Restrictions on sales activities and competition continue. - FY2021-Q2RestatedAnnual report
「Although testing volumes have been recovering since June, following the lifting of the state of emergency declared amid the spread of COVID-19, testing volumes declined during the cumulative second quarter of the current consolidated fiscal year.」
Although testing volumes have been recovering since the state of emergency was lifted, the decline in testing volumes continued during the cumulative second quarter. - FY2021-Q1Quantifying the decline in testing volumesAnnual report
「However, testing volumes declined 19.5% due to patients refraining from seeking medical care amid the spread of COVID-19.」
Patients refraining from seeking medical care due to COVID-19 was quantified as a 19.5% year-on-year decline in testing volumes. - FY2020Decline in testing demand due to COVID-19 becomes apparentAnnual report
「Against this backdrop, in the contract clinical testing industry, the number of tests contracted by medical institutions declined, as patients were presumed to have refrained from seeking medical care due to the impact of COVID-19. The business environment also remains challenging because intense competition among providers continues.」
In addition to the previously described coexistence of market growth and competition among providers, the full-year business environment now includes patients refraining from seeking medical care due to COVID-19 and a decline in the number of contracted tests. - FY2020-Q3RestatedAnnual report
「Against this backdrop, although the contract clinical testing market is growing, the business environment remains challenging because intense competition among providers continues.」
The company reiterated the business environment in which growth in the contract clinical testing market coexists with intense competition among providers. - FY2020-Q1First statedAnnual report
「Against this backdrop, although the contract clinical testing industry is experiencing market growth, the business environment remains challenging because intense competition among providers continues.」
The company explicitly described for the first time a business environment in which the contract clinical testing market is growing while intense competition among providers continues.